| Literature DB >> 28891953 |
Xinge Zhang1, Rui Zhang2, Justin B Moore3,4, Yueqiao Wang5, Hanyi Yan6, Yingru Wu7, Anran Tan8, Jialin Fu9, Ziqiong Shen10, Guiyu Qin11, Rui Li12, Guoxun Chen13.
Abstract
This meta-analysis evaluated the influence of dietary intake and blood level of vitamin A (total vitamin A, retinol or β-carotene) on total and hip fracture risk. Cohort studies published before July 2017 were selected through English-language literature searches in several databases. Relative risk (RR) with corresponding 95% confidence interval (CI) was used to evaluate the risk. Heterogeneity was checked by Chi-square and I² test. Sensitivity analysis and publication bias were also performed. For the association between retinol intake and total fracture risk, we performed subgroup analysis by sex, region, case ascertainment, education level, age at menopause and vitamin D intake. R software was used to complete all statistical analyses. A total of 319,077 participants over the age of 20 years were included. Higher dietary intake of retinol and total vitamin A may slightly decrease total fracture risk (RR with 95% CI: 0.95 (0.91, 1.00) and 0.94 (0.88, 0.99), respectively), and increase hip fracture risk (RR with 95% CI: 1.40 (1.02, 1.91) and 1.29 (1.06, 1.57), respectively). Lower blood level of retinol may slightly increase total fracture risk (RR with 95% CI: 1.11 (0.94, 1.30)) and hip fracture risk (RR with 95% CI: 1.27 (1.05, 1.53)). In addition, higher β-carotene intake was weakly associated with the increased risk of total fracture (RR with 95% CI: 1.07 (0.97, 1.17)). Our data suggest that vitamin A intake and level may differentially influence the risks of total and hip fractures. Clinical trials are warranted to confirm these results and assess the clinical applicability.Entities:
Keywords: hip fracture; retinol; total fracture; vitamin A; β-carotene
Mesh:
Substances:
Year: 2017 PMID: 28891953 PMCID: PMC5615580 DOI: 10.3390/ijerph14091043
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flow diagram of literature search.
Characteristics of studies on VA (total VA, retinol or β-carotene) intake.
| Author Year [ref.] | Country Period | Male/Female Age Case | Range of Exposure | Exposure Assessment | Case Ascertainment | Adjusted Variables | Quality Score |
|---|---|---|---|---|---|---|---|
| Feskanich et al., 2002 [ | U.S. 1980–1998 | 0/72,337 | Total VA μg RE/day | FFQ | Self-report | 1, 2, 3, 4, 9, 10, 11, 12, 14, 15, 17, 18, 23 | 8 |
| <1250; 1250–1699; 1700–2249; 2250–2999; ≥3000 | |||||||
| Retinol μg/day | |||||||
| <500; 500–849; 850–1299; 1300–1999; ≥2000 | |||||||
| β-carotene μg/day | |||||||
| <2550; 2550–3549; 3550–4669; 4650–6299; ≥6300 | |||||||
| Melhus et al., 1998 [ | SE 1987–1990 | 0/1120 | Retinol μg/day | FFQ | Medical records | 2, 5, 8, 9, 11, 12, 16, 17, 20, 32 | 7 |
| ≤500; 500–1000; 1000–1500; >1500 | |||||||
| Lim et al., 2004 [ | US 1985–1997 | 0/34,703 | Total VA IU | FFQ | Self-report | 1, 2, 7, 8, 10, 17, 19, 20, 24 | 6 |
| 221–7055; 7056–10484; 10,485–14,209; 14,210–19,892; 19,893–23,6991 | |||||||
| Retinol IU | |||||||
| 28–1405; 1406–2952; 2953–4655; 4656–7001; 7002–211,051 | |||||||
| Key et al., 2007 [ | UK 1993–2005 | 7947/26,749 | Retinol μg/day | FFQ | Self-report | 1, 2, 3, 4, 8, 9, 10, 11, 14, 22, 25, 26, 27, women for 21 and 12 | 8 |
| <200; 200–299; 300–499; 450–999; ≥1000 | |||||||
| β-carotene μg/day | |||||||
| <2000; 2000–2999; 3000–3999; 4000–4499; ≥5000 | |||||||
| Dai et al., 2014 [ | SG 1993–2010 | 27,959/35,298 | β-carotene 1000 kcal/day | FFQ | Medical records | 1, 2, 4, 7, 8, 9,11, 12, 13, 20, 29, 30, 31, 32 | 8 |
| <850.4; 580.4–1235.4; 1235.4–1772.4; ≥1772.4 | |||||||
| Cairejuvera et al., 2009 [ | U.S. 1993–2005 | 0/93676 | Total VA μg RE/day | FFQ | Self-report for total; Medical records for hip | 1, 2, 3, 4, 8, 9, 10, 11, 12, 14, 15, 18, 28, 31 | 8 |
| <5055; 5055–5824; 5825–6550; 6551–7507; ≥7508 | |||||||
| Retinol μg/day | |||||||
| <474; 474–764; 765–1092; 1093–1425; ≥1426 | |||||||
| Rejnmark et al., 2004 [ | DK 5 years | 0/2016 | Retinol μg/day | FFQ | Medical records | 1, 3, 4, 5, 6, 8, 9, 10, 11, 16, 17, 33, 34, 35, 36 | 8 |
| <500; 500–1500; >1500 | |||||||
| Jonge et al., 2015 [ | NED 1989–2007 | 2172/3116 ≥ 50 | Total VA μg RE/day | FFQ | Medical records | 1, 2, 4, 5, 7, 9, 10, 11, 12, 37, 38, 39 | 7 |
| 568–793; 867–1052; 1050–1257; 1263–1551; 1712–2485 | |||||||
| Retinol μg/day | |||||||
| 135–289; 173–384; 212–523; 272–734; 594–1518 | |||||||
| β-carotene μg/day | |||||||
| 1845–2909; 2942–3964; 3336–4575; 3586–5461; 3771–6586 |
VA: Vitamin A; RE: retinol equivalent (RE = μg retinol+(μg β-carotene/6) + (μg α-carotene/12) + (μg β-cryptoxanthin/24)); FFQ: food frequency questionnaire; Adjusted variables definition: 1: age; 2: BMI (body mass index); 3: vitamin D intake; 4: calcium intake; 5: age at: menopause; 6: vitamin D supplement intake; 7: education; 8: energy intake; 9: smoking; 10: alcohol intake; 11: physical activity; 12: hormone replacement therapy use; 13: year of recruitment; 14: protein intake; 15: vitamin K; 16: previous fracture; 17: medicine use; 18: caffeine intake; 19: cirrhosis; 20: diabetes mellitus; 21: parity; 22: marital status; 23: follow-up cycle; 24: past irregular menstrual duration; 25: vitamin C intake; 26: Potassium; 27: Magnesium; 28: region; 29: ethnic group; 30: soy isoflavones intake; 31: vitamin B6; 32: menopausal status: ; 33: weight; 34: bone mineral density; 35: VA intake; 36: β-carotene intake; 37: sex; 38: net income; 39: disability index.
Characteristics of studies on blood level of retinol.
| Author Year [ref.] | Country Period | Population/Age Case | Category of Blood Retinol (μmol/L) | Exposure Assessment | Case Ascertainment | Adjusted Variables | Quality Score |
|---|---|---|---|---|---|---|---|
| Michaelsson et al., 2003 [ | SE 1970–2001 | 2322/49–51 | The lowest: <1.95 The highest: >2.64 | High-performance liquid chromatography | Medical records | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 | 9 |
| Ambrosini et al., 2014 [ | AU 1990–2007 | 998/39–62 | The lowest: ≤2.80 The highest: ≥19.3 | High-performance liquid chromatography | Self-reported | 1, 8, 13,14, 15 | 6 |
| Holvik et al., 2015 [ | NO 1994–2008 | 2487/65–79 | The lowest: ≤2.12 The highest: >3.63 | High-performance liquid chromatography | Medical records | 1, 2, 16, 17 | 8 |
| Barker et al., 2005 [ | UK 1996–2002 | 2606/≥75 | The lowest: ≤1.66 The highest: ≥2.42 | High-performance liquid chromatography | Medical records | Total: 1, 18 Hip: 1, 3, 18 | 8 |
| Opotowsky et al., 2004 [ | U.S. 1971–1992 | 0/3571 | The lowest: ≤1.61 The highest: ≥2.56 | - | Medical records | 1, 3, 7, 11, 12, 14, 15, 19, 20 | 8 |
1: age; 2: BMI (body mass index); 3: weight; 4: height; 5: serum β-carotene; 6: serum calcium; 7: serum albumin; 8: smoking; 9: marital status; 10: socioeconomic class; 11: physical activity; 12: alcohol consumption; 13: sex; 14: medications; 15: previous fracture; 16: study center; 17: serum α-tocopherol; 18: total hip bone mineral density; 19: race; 20: dietary calcium intake.
Figure 2Association between VA (total VA or retinol or β-carotene) intake and risk of total or hip fracture. Boxes represent RR for each individual study; horizontal lines represent 95% CI; arrows indicate CI larger than 2.1; rhombus represent the combined RR with 95% CI.
Figure 3Association between blood level of retinol and risk of total or hip fracture. Boxes represent RR for each individual study; horizontal lines represent 95% CI; arrows indicate CI larger than 2.1; rhombus represent the combined RR with 95% CI.
Subgroup analyses for retinol intake and total fracture.
| Exposure | Subgroup | Number of Studies | RR (95% CI) | Q | I2 (%) | |
|---|---|---|---|---|---|---|
| Sex | Men | 1 | 0.80 (0.47, 1.36) | 0.00 | 1.00 | - |
| Women | 4 | 0.98 (0.92, 1.03) | 0.69 | 0.88 | 0.00% | |
| All | 1 | 0.86 (0.77, 0.96) | 0.00 | 1.00 | - | |
| Region | USA | 2 | 0.98 (0.92, 1.03) | 0.50 | 0.48 | 0.00% |
| Europe | 4 | 0.87 (0.79, 0.96) | 0.70 | 0.87 | 0.00% | |
| Case ascertainment | Self-report | 4 | 0.97 (0.92, 1.03) | 1.19 | 0.76 | 0.00% |
| Medical record | 2 | 0.87 (0.78, 0.96) | 0.32 | 0.57 | 0.00% | |
| Education level | Adjusted | 2 | 0.93 (0.90, 0.97) | 2.55 | 0.11 | 60.83% |
| Unadjusted | 4 | 0.99 (0.91, 1.07) | 0.94 | 0.82 | 0.00% | |
| Age at menopause | Adjusted | 2 | 0.87 (0.78, 0.96) | 0.32 | 0.57 | 0.00% |
| Unadjusted | 4 | 0.97 (0.92, 1.03) | 1.19 | 0.76 | 0.00% | |
| Vitamin D intake | Adjusted | 3 | 0.95 (0.87, 1.02) | 4.63 | 0.099 | 58.31% |
| Unadjusted | 3 | 0.92 (0.75, 1.13) | 0.40 | 0.82 | 0.00% |
Sensitivity analyses and publication bias.
| Group | Omitted Study | RR (95% CI) | Q | I2 (%) | Z-Egger | ||
|---|---|---|---|---|---|---|---|
| Total VA intake for total fracture | Cairejuvera et al., [ | 0.93 (0.86, 1.00) | 3.03 | 0.08 | 67.01% | −1.3982 | 0.16 |
| Lim et al., [ | 0.96 (0.90, 1.03) | 0.22 | 0.64 | 0.00% | |||
| Feskanich et al., [ | 0.91 (0.85, 0.98) | 1.89 | 0.17 | 47.11% | |||
| Total VA for hip fracture | Jonge et al., [ | 1.34 (1.08, 1.67) | 0.55 | 0.46 | 0.00% | −0.1893 | 0.85 |
| Cairejuvera et al., [ | 1.21 (0.96, 1.53) | 0.13 | 0.72 | 0.00% | |||
| Lim et al., [ | 1.33 (1.02, 1.72) | 0.93 | 0.34 | 0.00% | |||
| Retinol intake for total fracture | Jonge et al., [ | 0.95 (0.90, 1.00) | 5.07 | 0.28 | 36.04% | 0.6236 | 0.53 |
| Cairejuvera et al., [ | 0.95 (0.91, 1.00) | 5.10 | 0.28 | 39.45% | |||
| Key et al. (M), [ | 0.95 (0.91, 1.00) | 4.73 | 0.32 | 34.86% | |||
| Key et al. (F), [ | 0.93 (0.87, 0.98) | 2.96 | 0.56 | 20.26% | |||
| Lim et al., [ | 0.97 (0.92, 1.03) | 1.22 | 0.87 | 0.00% | |||
| Rejnmark et al., [ | 0.94 (0.89, 1.00) | 5.02 | 0.29 | 37.52% | |||
| Retinol intake for hip fracture | Cairejuvera et al., [ | 1.54 (1.02, 2.33) | 7.13 | 0.028 | 69.57% | 1.3639 | 0.17 |
| Lim et al., [ | 1.57 (1.06, 2.31) | 5.29 | 0.07 | 60.93% | |||
| Feskanich et al., [ | 1.17 (0.96, 1.43) | 2.96 | 0.23 | 0.01% | |||
| Melhus et al., [ | 1.31 (0.94, 1.84) | 6.48 | 0.039 | 70.25% | |||
| β-carotene intake for total fracture | Jonge et al., [ | 1.04 (0.94, 1.16) | 0.61 | 0.44 | 0.00% | −0.4368 | 0.66 |
| Key et al. (F), [ | 1.08 (0.98, 1.18) | 0.54 | 0.46 | 0.00% | |||
| Key et al. (M), [ | 1.09 (0.93, 1.29) | 1.16 | 0.28 | 14.10% | |||
| β-carotene intake for hip fracture | Dai et al. (M), [ | 0.88 (0.46, 1.68) | 8.76 | 0.03 | 88.59% | −0.2493 | 0.80 |
| Dai et al. (F), [ | 1.05 (0.85, 1.30) | 1.62 | 0.20 | 38.10% | |||
| Feskanich et al., [ | 0.80 (0.52, 1.22) | 5.45 | 0.02 | 81.64% | |||
| High level of blood retinol for total fracture | Michaelsson et al., [ | 0.87 (0.71, 1.07) | 0.75 | 0.39 | 0.00% | 0.4619 | 0.64 |
| Ambrosini et al., [ | 1.16 (0.61, 2.20) | 8.78 | 0.003 | 88.61% | |||
| Barker et al., [ | 1.52 (1.09, 2.13) | 0.64 | 0.42 | 0.00% | |||
| High level of blood retinol for hip fracture | Michaelsson et al., [ | 1.15 (0.82, 1.61) | 6.78 | 0.079 | 57.69% | 2.7952 | 0.005 |
| Barker et al., [ | 1.41 (0.87, 2.29) | 10.27 | 0.016 | 70.12% | |||
| Holvik et al. (M), [ | 1.37 (0.85, 2.21) | 10.79 | 0.013 | 76.05% | |||
| Holvik et al. (F), [ | 1.46 (0.95, 2.24) | 7.67 | 0.053 | 61.11% | |||
| Opotowsky et al., [ | 1.08 (0.84, 1.40) | 5.62 | 0.13 | 23.13% | |||
| Low level of blood retinol for total fracture | Michaelsson et al., [ | 1.15 (0.96, 1.36) | 0.04 | 0.85 | 0.00% | −0.6384 | 0.52 |
| Ambrosini et al., [ | 1.11 (0.94, 1.31) | 0.88 | 0.35 | 0.00% | |||
| Barker et al., [ | 0.96 (0.68, 1.37) | 0.11 | 0.74 | 0.00% | |||
| Low level of blood retinol for hip fracture | Michaelsson et al., [ | 1.26 (1.04, 1.54) | 2.65 | 0.45 | 0.00% | 0.8156 | 0.41 |
| Barker et al., [ | 1.27 (1.01, 1.60) | 2.66 | 0.45 | 0.00% | |||
| Holvik et al. (F), [ | 1.35 (1.06, 1.71) | 1.92 | 0.59 | 0.00% | |||
| Holvik et al. (M), [ | 1.28 (1.04, 1.57) | 2.58 | 0.46 | 0.00% | |||
| Opotowsky et al., [ | 1.20 (0.98, 1.47) | 0.29 | 0.96 | 0.00% |